Image Place holder

Iman Imanirad, MD


Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • University of Florida College of Medicine - Hematology Oncology

Residency:

  • University of Florida College of Medicine - Internal Medicine

Medical School:

  • Saba University of Medical Sciences - MD
Participating Trials

CLINICAL TRIAL 18051
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition:
Intervention: MGD007
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition:
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 19091
A Phase I/II Study of Pembrolizumab in Combination with Ibrutinib for Advanced, Refractory Colorectal Cancers
Condition:
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 19460
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients with Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C
Condition:
Intervention: TAK-164
Open

CLINICAL TRIAL 19594
A Multicenter, Non-Randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma (HCC) with No Prior Systemic Therapy.
Condition:
Intervention:
Open

CLINICAL TRIAL 19483
A Phase III, Open-Label, Randomized Study Of Atezolizumab In Combination With Bevacizumab Compared With Sorafenib In Patients With Untreated Locally Advanced Or Metastatic Hepatocellular Carcinoma
Condition:
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); BAY 43-9006 (Sorafenib); Bevacizumab; Sorafenib
Open

CLINICAL TRIAL 19615
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 x CD3 DART Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma
Condition:
Intervention: MGA012; MGD007
Open

CLINICAL TRIAL 19597
A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with resectable Cholangiocarcinoma
Condition:
Intervention: Atezolizumab (Tecentriq); Cobimetinib
Open

CLINICAL TRIAL 19732
Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (Cabinet)
Condition:
Intervention:
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Cogle CR, Iannacone MR, Yu D, Cole AL, Imanirad I, Yan L, Mackinnon JA, List AF, Rollison DE. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res. 2014 Jan;38(1):71-75. Pubmedid: 24280283.
  • Dallas J, Imanirad I, Rajani R, Dagan R, Subbiah S, Gaa R, Dwarica WA, Ivey AM, Zlotecki RA, Malyapa R, Indelicato DJ, Scarborough MT, Reith JD, Gibbs CP, Dang LH. Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report. J Med Case Rep. 2012 Jan;6:41. Pubmedid: 22289277. Pmcid: PMC3277477.
  • Imanirad I, Rajasekhar A, Zumberg M. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher. 2012 Aug;27(4):221-226. Pubmedid: 22467376.
  • Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH. Combination therapy for renal cell cancer: what are possible options?. Oncology-Basel. 2012 Apr;81(3-4):220-229. Pubmedid: 22085914. Pmcid: PMC3225259.
  • Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC, Wingard JR. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol. 2010 Jan;8(1):40-46. Pubmedid: 20351682.